Our new Japanese recruitment team delivers volunteer panels - already!

Posted:
16
December 2004

Volunteers enjoying a study

Richmond Pharmacology's new dedicated Japanese recruitment team have successfully delivered 2 Japanese panels for Bridging Studies in November and December this year. We are already ahead of target for our Japanese/Caucasian Bridging Studies requirements in 2005.As a result of the continued growth in the demand for Bridging Studies, Richmond Pharmacology have developed a dedicated in-house approach to the recruitment of Japanese volunteer panels.Wendy Galloway, Head of Volunteer Recruitment, commented: “We recognised the need to introduce a stronger means of recruiting Japanese volunteers. Consequently, in September we recruited 5 bilingual Japanese recruitment managers and have introduced a specialist marketing strategy to support this. I am delighted with the results – in just 2 months since the launch we have successfully delivered 2 Japanese volunteer panels. Our campaigns currently stretch across the UK and Germany and through this approach we are already ahead of target for the New Year's requirements. This means we continue to offer our clients a volunteer recruitment guarantee on every Phase I study.”Richmond Pharmacology is Europe's largest provider of Japanese/Caucasian Bridging Studies and has a dedicated Japanese recruitment brand and department. For more information click here.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more